$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

$ohcs Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022071111 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$217.9K	$347.2K	$147.3K
YoY Change		135.67%	-23.17%
Cost Of Revenue	$60.82K	$65.02K	$46.00K
YoY Change		41.35%	311.82%
Gross Profit	$157.1K	$282.1K	$101.3K
YoY Change		178.49%	-43.89%
Gross Profit Margin	72.09%	81.27%	68.77%
Selling, General & Admin	-$149.3K	$2.651M	$3.041M
YoY Change		-12.81%	502.71%
% of Gross Profit	-94.99%	939.77%	3001.85%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$149.1K	-$1.950K	$350.00
YoY Change		-657.14%	94.44%
% of Gross Profit	94.88%	-0.69%	0.35%
Operating Expenses	-$149.3K	$2.651M	$3.041M
YoY Change		-12.81%	502.71%
Operating Profit	$306.4K	-$2.369M	-$2.940M
YoY Change		-19.41%	807.34%
Interest Expense	-$126.3K	$104.3K	-$82.34K
YoY Change		-226.66%	5781.43%
% of Operating Profit	-41.23%
Other Income/Expense, Net	-$291.3K	-$721.0K	-$277.3K
YoY Change		160.04%
Pretax Income	-$193.2K	-$3.090M	-$3.299M
YoY Change		-6.34%	913.94%
Income Tax	$7.680K	$0.00
% Of Pretax Income
Net Earnings	-$200.6K	-$3.090M	-$23.36K
YoY Change		13128.97%	-85.35%
Net Earnings / Revenue	-92.05%	-890.16%	-15.86%
Basic Earnings Per Share		-$0.08	-$0.14
Diluted Earnings Per Share	-$0.01	-$0.10	-$901.00
COMMON SHARES
Basic Shares Outstanding	40.29M shares	40.29M shares	22.64M shares
Diluted Shares Outstanding		40.17M shares	22.64M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.000M	$1.078M	$1.965M
YoY Change		-45.16%
Cash & Equivalents	$751.0K	$680.9K	$1.218M
Short-Term Investments	$249.1K	$396.9K	$747.7K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$525.1K	$602.9K	$554.1K
Other Receivables	$200.7K	$0.00	$365.0K
Total Short-Term Assets	$1.726M	$1.681M	$2.884M
YoY Change	-16.78%	-41.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.20K	$30.32K	$4.710K
YoY Change	1144.38%	543.74%
Goodwill	$815.5K	$3.636M
YoY Change	-71.09%
Intangibles	$2.750K	$1.703M
YoY Change	-99.86%
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$1.214M	$5.725M	$4.726M
YoY Change	-78.74%	21.13%
TOTAL ASSETS
Total Short-Term Assets	$1.726M	$1.681M	$2.884M
Total Long-Term Assets	$1.214M	$5.725M	$4.726M
Total Assets	$2.940M	$7.406M	$7.611M
YoY Change	-62.23%	-2.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$738.4K	$1.588M	$975.6K
YoY Change	-13.26%	62.75%
Accrued Expenses	$581.8K	$65.22K
YoY Change	44.83%
Deferred Revenue
YoY Change
Short-Term Debt	$140.3K	$142.6K	$177.0K
YoY Change		-19.42%
Long-Term Debt Due	$5.300K	$5.300K	$7.660K
YoY Change		-30.81%
Total Short-Term Liabilities	$1.533M	$1.801M	$1.160M
YoY Change	8.18%	55.22%
LONG-TERM LIABILITIES
Long-Term Debt	$2.767M	$2.476M	$544.8K
YoY Change		354.58%
Other Long-Term Liabilities	$283.1K	$300.6K
YoY Change
Total Long-Term Liabilities	$3.050M	$2.777M	$544.8K
YoY Change		409.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.533M	$1.801M	$1.160M
Total Long-Term Liabilities	$3.050M	$2.777M	$544.8K
Total Liabilities	$4.582M	$4.578M	$1.292M
YoY Change	93.24%	254.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.03M	-$18.83M
YoY Change	129.1%
Common Stock	$38.29K	$40.29K
YoY Change	45.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.641M	$2.829M	$6.319M
YoY Change
Total Liabilities & Shareholders Equity	$2.940M	$7.406M	$7.611M
YoY Change	-62.23%	-2.7%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$200.6K	-$3.090M	-$23.36K
YoY Change		13128.97%	-85.35%
Depreciation, Depletion And Amortization	$149.1K	-$1.950K	$350.00
YoY Change		-657.14%	94.44%
Cash From Operating Activities	-$1.005M	-$880.1K	-$2.110M
YoY Change		-58.29%	7495.82%
INVESTING ACTIVITIES
Capital Expenditures	$28.16K	-$21.88K	-$5.060K
YoY Change		332.41%
Acquisitions
YoY Change
Other Investing Activities	-$100.0K	$0.00	-$967.8K
YoY Change		-100.0%
Cash From Investing Activities	-$128.2K	-$21.88K	-$972.9K
YoY Change		-97.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.203M	371.2K	3.259M
YoY Change		-88.61%	2242.71%
NET CHANGE
Cash From Operating Activities	-1.005M	-880.1K	-2.110M
Cash From Investing Activities	-128.2K	-21.88K	-972.9K
Cash From Financing Activities	1.203M	371.2K	3.259M
Net Change In Cash	70.14K	-530.8K	175.7K
YoY Change		-402.11%	57.82%
FREE CASH FLOW
Cash From Operating Activities	-$1.005M	-$880.1K	-$2.110M
Capital Expenditures	$28.16K	-$21.88K	-$5.060K
Free Cash Flow	-$1.033M	-$858.2K	-$2.105M
YoY Change		-59.23%	7477.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41210
	dei	Entity Registrant Name EntityRegistrantName	OPTIMUS HEALTHCARE SERVICES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0181535
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1400 Old Country Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 306
	dei	Entity Address City Or Town EntityAddressCityOrTown	Westbury
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11590
	dei	City Area Code CityAreaCode	(516)
	dei	Local Phone Number LocalPhoneNumber	806-4201
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40286598	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	680876	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260838	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	602875	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	474638	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27026	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10945	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	369850	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1327440	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	1680627	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2073861	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	356056	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	318717	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30320	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4516	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1702812	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1899748	usd
CY2022Q3	us-gaap	Goodwill Goodwill	3635845	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2820345	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	666616	usd
CY2022Q3	us-gaap	Assets Assets	7405660	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1190431	usd
CY2022Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	141816	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	150079	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	617	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	617	usd
CY2021Q4	us-gaap	Assets Assets	7783803	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1587778	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21612197	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	200	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	25200	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	5304	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	5304	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65219	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45224	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1800934	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1416855	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	300636	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	279968	usd
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2468643	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	663014	usd
CY2022Q3	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	7796	usd
CY2021Q4	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	11482	usd
CY2022Q3	us-gaap	Liabilities Liabilities	4578009	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2371319	usd
CY2022Q3	ohcs	Preferred Stock Value1 PreferredStockValue1	2	usd
CY2021Q4	ohcs	Preferred Stock Value1 PreferredStockValue1	10001	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	8106	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	8106	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40286598	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40286598	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26225974	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26225974	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	40287	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	26226	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13676762	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18831946	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8307686	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	2828646	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5413409	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-995	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-925	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2827651	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5412484	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7405660	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7783803	usd
CY2022Q3	us-gaap	Revenues Revenues	347159	usd
CY2021Q3	us-gaap	Revenues Revenues	148259	usd
	us-gaap	Revenues Revenues	1000945	usd
	us-gaap	Revenues Revenues	623185	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	65020	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	39760	usd
	us-gaap	Cost Of Revenue CostOfRevenue	201873	usd
	us-gaap	Cost Of Revenue CostOfRevenue	145041	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	282139	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	108499	usd
	us-gaap	Gross Profit GrossProfit	799072	usd
	us-gaap	Gross Profit GrossProfit	478144	usd
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1304512	usd
CY2021Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2308044	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	5191214	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2767357	usd
CY2022Q3	ohcs	Personnel Expenses PersonnelExpenses	715028	usd
CY2021Q3	ohcs	Personnel Expenses PersonnelExpenses	368162	usd
	ohcs	Personnel Expenses PersonnelExpenses	1757339	usd
	ohcs	Personnel Expenses PersonnelExpenses	989260	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	517636	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	154747	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1750636	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	636120	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	114276	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	83948	usd
	us-gaap	Professional Fees ProfessionalFees	472427	usd
	us-gaap	Professional Fees ProfessionalFees	491601	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2651452	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2914901	usd
	us-gaap	Operating Expenses OperatingExpenses	9171616	usd
	us-gaap	Operating Expenses OperatingExpenses	4884338	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2369313	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2806402	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8372544	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4406194	usd
CY2022Q3	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	291318	usd
CY2021Q3	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	277261	usd
	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	840311	usd
	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	385754	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	104291	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	77866	usd
	us-gaap	Interest Expense InterestExpense	223015	usd
	us-gaap	Interest Expense InterestExpense	101720	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-264261	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-264261	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-61111	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-19474	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-157590	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.76
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P10Y
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-19474	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-720974	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-359601	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1485170	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-491948	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	666616	usd
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-77	usd
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	13716	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-70	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-143820	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3090210	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3179719	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10524260	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4754322	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3090287	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-3166003	usd
	us-gaap	Profit Loss ProfitLoss	-10524330	usd
	us-gaap	Profit Loss ProfitLoss	-4898142	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40173220	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22638115	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38425341	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16993671	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5412484	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	467500	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2481510	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3644058	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4717436	usd
CY2022Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	375000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	111847	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	857835	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1405193	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-3789985	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3677326	usd
CY2022Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	375000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	561100	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1304512	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3090287	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2827651	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	444353	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1160000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4560000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	928762	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2767357	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	88691	usd
	ohcs	Fair Value Of Beneficial Conversion Feature FairValueOfBeneficialConversionFeature	982547	usd
	us-gaap	Profit Loss ProfitLoss	-4898142	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6033568	usd
	us-gaap	Profit Loss ProfitLoss	-10524330	usd
	us-gaap	Profit Loss ProfitLoss	-4898142	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200766	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	347	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5191214	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2767357	usd
	us-gaap	Interest Income Other InterestIncomeOther	15000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-157590	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-264261	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	840311	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	385754	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3324	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	666616	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	128238	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-32619	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	16081	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	58961	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	311938	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-177702	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3032629	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1963728	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-9000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-82157	usd
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	350000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2203666	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1403666	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	29384	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	5061	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	779616	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-272904	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	750000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1160000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1935000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	148975	usd
	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	3686	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	8263	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	43712	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2673051	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3265263	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	420038	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1028631	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260838	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1041890	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	680876	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2070521	usd
	us-gaap	Interest Paid Net InterestPaidNet	99000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of operations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optimus Healthcare Services, Inc. (formerly Between Dandelions, Inc., “Optimus”, “Company”) was initially organized under the laws of Florida on February 26, 1990, as Phoenix Management Associates, Inc. Over the ensuing years, the Company made a series of amendments to its Articles of Incorporation relating to authorization of various series of Preferred Shares and made a series of name changes. The current name of Optimus Healthcare Services, Inc. became effective with the State of Florida on January 24, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is dedicated to: (1) improving patient/physician interactions and outcomes through the acquisition and deployment of telehealth and compliance technologies (TACT); (2) advancing access to clinical trial research; and (3) improving and simplifying access to vaccines and pharmaceutical products. Currently the Company provides these services through its portfolio companies, AdhereRx Corporation (d/b/a PainScript), Clinical Research Alliance, Inc. (CRA), and Worker’s Health Rx (d/b/a Vitality Rx).</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services, valuation of equity associated with convertible debt, the valuation of derivative liabilities, and the valuation of deferred tax assets. Actual results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"> </p>
	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">The Company recognizes revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “<i>Revenue from contracts with customers,”</i> (Topic 606). Revenue is recognized when a customer obtains control of promised goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company’s main revenue stream is from services. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">For services performed by CRA, the Company’s performance obligations are generally met at the point in time the services are rendered.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adhere Rx, Inc. provides software services primarily to physicians and physician groups through a cloud software as a service (SaaS) platform through which the physicians and physician groups will be billed on a periodic basis for the services. Adhere Rx, Inc. will typically meet its performance obligations over a period of time. Revenues will be recognized ratable over the related contractual term of the service. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	296250	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	55000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	505000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	378750	shares
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	5191214	usd
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	2767357	usd
	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	179	usd
	ohcs	Interest Rate Of Lease InterestRateOfLease	0.075	pure
	us-gaap	Advertising Expense AdvertisingExpense	17150	usd
	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.50	pure
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	252979	usd
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	402628	usd
CY2022Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	68108	usd
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	77436	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	365855	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	325192	usd
CY2022Q3	ohcs	Office Lease OfficeLease	456819	usd
CY2021Q4	ohcs	Office Lease OfficeLease	371832	usd
CY2022Q3	ohcs	Equipment Lease EquipmentLease	5611	usd
CY2021Q4	ohcs	Equipment Lease EquipmentLease	5611	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	106374	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	58726	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	356056	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	318717	usd
CY2022Q3	ohcs	Office Lease Liability OfficeLeaseLiability	363300	usd
CY2021Q4	ohcs	Office Lease Liability OfficeLeaseLiability	321214	usd
CY2022Q3	ohcs	Equipment Lease Liability EquipmentLeaseLiability	2555	usd
CY2021Q4	ohcs	Equipment Lease Liability EquipmentLeaseLiability	3978	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65219	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45224	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	300636	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	279968	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	21938	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	69094	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	88907	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	69834	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	91335	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	69477	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	93837	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	71323	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	88269	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	73223	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	49677	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	49677	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	433963	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	680876	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260838	usd
CY2022Q3	us-gaap	Capital Units Net Amount CapitalUnitsNetAmount	120307	usd
CY2021Q4	us-gaap	Capital Units Net Amount CapitalUnitsNetAmount	657006	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	10524330	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	4898142	usd
	ohcs	Going Concern Term GoingConcernTerm	P1Y
CY2020Q4	us-gaap	Debtor In Possession Financing Interest Rate On Borrowings Outstanding DebtorInPossessionFinancingInterestRateOnBorrowingsOutstanding	1	pure
CY2020Q4	ohcs	Business Acquisition Percentage Of Voting Interest Acquired BusinessAcquisitionPercentageOfVotingInterestAcquired	0.73	pure
CY2021Q3	us-gaap	Memberships In Exchanges Owned MembershipsInExchangesOwned	425000	usd
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	1
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	1.25
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	28540	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	11555	usd
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	23896	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3904	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52436	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15459	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22116	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10943	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30320	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4516	usd
	us-gaap	Depreciation Depreciation	1668	usd
CY2022Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	250000	usd
	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0164	pure
CY2022Q3	us-gaap	Line Of Credit LineOfCredit	8263	usd
	us-gaap	Development Costs DevelopmentCosts	2026245	usd
CY2021	us-gaap	Development Costs DevelopmentCosts	2026245	usd
	ohcs	Website Website	3000	usd
CY2022Q3	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	326433	usd
CY2021Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	126497	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1702812	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1899748	usd
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	199098	usd
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	0	usd
CY2022Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	527440	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1350000	usd
	ohcs	Gross Unrealized Loss GrossUnrealizedLoss	-157590	usd
CY2021	ohcs	Gross Unrealized Loss GrossUnrealizedLoss	-22560	usd
	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	369850	usd
CY2021	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	1327440	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	157590	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	9	usd
CY2022Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	141816	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	150079	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	617	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	617	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	617	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	617	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	200	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	25200	usd
CY2011Q1	ohcs	Issued1 Issued1	10000	usd
CY2021Q4	ohcs	No Coupon Due On Demand Issued One NoCouponDueOnDemandIssuedOne	10000	usd
CY2016Q4	ohcs	Issued2 Issued2	15000	usd
CY2021Q4	ohcs	No Coupon Due On Demand Issued Two NoCouponDueOnDemandIssuedTwo	15000	usd
CY2020Q4	ohcs	Issued3 Issued3	10100	usd
CY2022Q3	ohcs	No Coupon Due On Demand Issued Three NoCouponDueOnDemandIssuedThree	200	usd
CY2021Q4	ohcs	No Coupon Due On Demand Issued Three NoCouponDueOnDemandIssuedThree	200	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	200	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	25200	usd
CY2022Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	362000	shares
CY2022Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	25000	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	271839	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	264261	usd
CY2020Q2	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	145683	usd
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	223015	usd
	ohcs	Amortization Of Debt Discount AmortizationOfDebtDiscount	840311	usd
CY2021Q1	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	148975	usd
CY2022Q3	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
CY2020Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	The unforgiven portion of the PPP loan totaling $19,137 is payable over five years at an interest rate of 1%, with a deferral of payments for the first twelve months.
CY2022Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	7796	usd
CY2022Q2	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	5304	usd
CY2021Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	148975	usd
	us-gaap	Loan Portfolio Expense LoanPortfolioExpense	3686	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2468643	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	663014	usd
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2200000	usd
CY2021Q2	us-gaap	Debt Instrument Description DebtInstrumentDescription	On May 25, 2021, the Company entered into a securities purchase agreement with certain institutional investors (collectively, the “May 2021 Investors”) pursuant to which the Company issued convertible notes in an aggregate principal amount of $2,200,000 for an aggregate purchase price of $2 million (collectively, the “May 2021 Notes”). In connection with the issuance of the May 2021 Notes, the Company issued to the May 2021 Investors warrants to purchase an aggregate of 165,000 shares of common stock (collectively, the “Warrants”) and 1,727,859 shares of common stock. The May 2021 Notes accrue interest at a rate of 9% per annum, subject to increase to 20% per annum upon and during the occurrence of an event of default. Interest is payable in cash on a quarterly basis. The May 2021 Notes are convertible at any time, at the holder’s option, into shares of the Company’s common stock at a conversion price of $1.00 per share, subject to certain beneficial ownership limitations (with a maximum ownership limit of 9.99%). The conversion price is also subject to adjustment due to certain events, including stock dividends and stock splits. Each Warrant is exercisable for a period of five years from the date of issuance at an initial exercise price of $1.25 per share, subject to certain beneficial ownership limitations (with a maximum ownership limit of 9.99%).
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2200000	usd
CY2022Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	2200000	usd
CY2022Q2	ohcs	Aggregate Purchase Price AggregatePurchasePrice	2000000	usd
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1
CY2022Q2	ohcs	Equity Method Investments Ownership Percentages EquityMethodInvestmentsOwnershipPercentages	0.0999	pure
	ohcs	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerms	P5Y
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.25
CY2022Q3	ohcs	Equity Method Investments Ownership Percentages EquityMethodInvestmentsOwnershipPercentages	0.0999	pure
CY2022Q3	us-gaap	Demutualization By Insurance Entity Securities Issued Quantity Of Shares DemutualizationByInsuranceEntitySecuritiesIssuedQuantityOfShares	2000000	shares
CY2022Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	1
CY2022Q2	us-gaap	Demutualization By Insurance Entity Securities Issued Quantity Of Shares DemutualizationByInsuranceEntitySecuritiesIssuedQuantityOfShares	5000000	shares
CY2022Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	1
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2200000	shares
CY2021Q4	ohcs	Equity Method Investment Ownership Percentages EquityMethodInvestmentOwnershipPercentages	700000.01	pure
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	9998899	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5297500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.74
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y5M4D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1235000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	250000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6282500	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.74
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M6D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1735625	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.7
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y10M6D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5191214	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6271971	usd
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	425000	usd
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	425000	shares
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7751779	usd
CY2021	ohcs	Increase In Optimus Healthcare Services Inc Ownership Interests In Craac From51 To9988 IncreaseInOptimusHealthcareServicesIncOwnershipInterestsInCRAACFrom51To9988	-274400	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8026179	usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	666616	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	666616	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	666616	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.1287	pure
	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.0196	pure
	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0059	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0676	pure
CY2017Q4	srt	Taxable Investment Securities Average Yield TaxableInvestmentSecuritiesAverageYield	0.80	pure
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	193000	usd
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4800000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1241174	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	601151	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	286874	usd
CY2022Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	95616	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	68290	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	39888	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	51345	usd
CY2022Q3	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	52198	usd
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	12553	usd
CY2022Q3	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	6826	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	1155	usd
CY2022Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	40547	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1763123	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	734494	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	382911	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	948	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	93055	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	66930	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	475966	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	67878	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1287157	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	666616	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1287157	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	666616	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22638115	shares
CY2022Q1	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities		usd
	us-gaap	Interest Income Other InterestIncomeOther		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	ohcs	Stock Issued Business Acquisition StockIssuedBusinessAcquisition		usd
	ohcs	Stock Issued Business Acquisition StockIssuedBusinessAcquisition		usd
	us-gaap	Depreciation Depreciation		usd
CY2021	ohcs	Website Website		usd
	ohcs	Gross Unrealized Gain GrossUnrealizedGain		usd
CY2021	ohcs	Gross Unrealized Gain GrossUnrealizedGain		usd
CY2022Q3	ohcs	No Coupon Due On Demand Issued Two NoCouponDueOnDemandIssuedTwo		usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	ohcs	Sharebased Compensation Arrangement By Weighted Average Remaining Term Options Exercised SharebasedCompensationArrangementByWeightedAverageRemainingTermOptionsExercised
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
	ohcs	Sharebased Compensation Arrangement By Weighted Average Remaining Term Options Cancelled SharebasedCompensationArrangementByWeightedAverageRemainingTermOptionsCancelled
CY2021	ohcs	Transfersto From The Noncontrolling Interest TransferstoFromTheNoncontrollingInterest		usd
CY2021	ohcs	Net Transfers Fromto Noncontrolling Interest NetTransfersFromtoNoncontrollingInterest		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001892025

Files In Submission

Name	View Source	Status
ohcs-20220930_cal.xml	Edgar Link	unprocessable
0001213900-22-071111-index-headers.html	Edgar Link	pending
0001213900-22-071111-index.html	Edgar Link	pending
0001213900-22-071111.txt	Edgar Link	pending
0001213900-22-071111-xbrl.zip	Edgar Link	pending
f10q0922ex31-1_optimushealth.htm	Edgar Link	pending
f10q0922ex31-2_optimushealth.htm	Edgar Link	pending
f10q0922ex32-1_optimushealth.htm	Edgar Link	pending
f10q0922ex32-2_optimushealth.htm	Edgar Link	pending
f10q0922_optimushealth.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ohcs-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ohcs-20220930_lab.xml	Edgar Link	unprocessable
ohcs-20220930_def.xml	Edgar Link	unprocessable
ohcs-20220930_pre.xml	Edgar Link	unprocessable
f10q0922_optimushealth_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

2022 Q4 Form 10-Q Financial Statement

#000121390022071111 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS Optimus Healthcare Services, Inc. Stock $ohcs

2022 Q4 Form 10-Q Financial Statement

#000121390022071111 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs